Implementation for USP ‹467› was pushed back from July 1, 2007 to July 1, 2008 to allow the industry time to prepare. But even so, analysts worry
it may not be enough time. "The regulations have been changed so much and it's been so drawn out that I've got a feeling that
a lot of people are behind on this and they are going to be in scramble mode real soon," predicts Schumacher.
FDA plans to issue a Federal Register notice that would clarify when compliance with the USP ‹467› specifications should be reported. A draft is in the works and is currently undergoing the approval process. For products
that are already marketed under an NDA or ANDA, manufacturers would report their compliance with USP ‹467› in the next annual report. "I don't think we will require them to include a lot of analytical detail in the annual
report," says Ouderkirk. "For example, they may have developed methodologies to comply with ‹467›, and rather than having
supplements filed we're just looking to an annual report for them to notify us that they are compliant. We are trying to avoid
triggering a lot of supplements from the industry." New NDAs should take ‹467› requirements into consideration. "If I were
filing something today, I would want to note that I am complying with ‹467› no later than July 1," says Ouderkirk.
Other organizations also are planning to help clarify the lingering concerns about methods, applications, and changes brought
about by USP ‹467›. At its annual scientific meeting in September, USP hosted a track section solely on the issue of residual solvents,
and additional training sessions are in the works. Several pharmaceutical laboratories are also planning and sponsoring events
and offer their expertise on validated methodologies. These efforts are timely and, apparently, in great need. "I would say
it's really about a 50–50 mix of pharmaceutical companies that are fully on board with what is going on here, with 50% that
are behind the 8 ball and not really understanding what their responsibility is going to be with this. From a client perspective
it seems like some folks haven't kept up with what's going on as to how this has changed," says Emig.
1. Lancaster Laboratories, internal publication on USP ‹467›, available at